Pennant Group

PNTG · NASDAQ

$41.48+$0.82 (+2.02%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $40.66

PNTG analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $47.60 (+14.8% upside)

Low: $44.44
Now: $41.48
High: $51.45

Upgrades and downgrades

The latest rating actions, newest first

PNTG analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Aug 20, 2026	Maintains	Outperform	$42.00 → $44.00	57%
Wells Fargo	Aug 11, 2026	Maintains	Overweight	$45.00 → $46.00	59%
Truist Securities	Jul 14, 2026	Maintains	Buy	$42.00 → $48.00	67%
Wells Fargo	Jul 13, 2026	Maintains	Overweight	$41.00 → $45.00	59%
RBC Capital	May 8, 2026	Maintains	Outperform	$41.00 → $42.00	57%
Truist Securities	May 8, 2026	Maintains	Buy	$36.00 → $42.00	67%
Wells Fargo	May 8, 2026	Maintains	Overweight	$38.00 → $41.00	59%
Truist Securities	Apr 13, 2026	Maintains	Buy	$34.00 → $36.00	67%
RBC Capital	Mar 2, 2026	Maintains	Outperform	$39.00 → $41.00	57%
Wells Fargo	Jan 7, 2026	Maintains	Overweight	$31.00 → $38.00	59%

The case for and against

Updated Oct 17, 2026

Bull case

Pennant Gr is supported by strong same-store momentum across its home health, hospice, and senior living businesses, with second quarter results beating Street expectations and management raising full-year 2026 guidance to revenue of $1,171.1MM-$1,190.1MM and adjusted EBITDA of $94.4MM-$98.0MM. Core operating trends are improving, including SS home health admissions up 9.7% YOY, SS Medicare home health admissions up 13.6% YOY, SS hospice ADC up 10.8% YOY to 4,089, and senior living occupancy rising 150 bps YOY to 81.6% with same-store RevPOR up 5.5% YOY to $5,413. The outlook is further strengthened by ahead-of-schedule integration of the former UNH/AMED assets, improving clinical quality metrics, and a more favorable reimbursement backdrop after four consecutive years of home health base rate cuts.

Bear case

Pennant Gr is exposed to meaningful downside because its home health and hospice businesses depend heavily on Medicare reimbursement, while the downside case assumes topline momentum plateaus and labor pressures compress margins. The analysis also highlights execution risk from a rapid expansion strategy, since unforeseen integration headwinds in transitioning assets could force management to halt incremental M&A and slow growth. In addition, senior housing may face occupancy pressure from supply headwinds, and FY27E EBITDAR is projected to land 5% below current estimates, supporting a weaker 8.0x to 10.7x valuation multiple.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.